A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

COVID 19 Associated Coagulopathy Clinical Trial

Official title: A Study of the Efficacy of Troxerutin in Preventing Thrombotic Events in COVID-19 Patients

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to learn if troxerutin works to prevent thrombotic events in mild or severe COVID-19 patients. It will also learn about the safety of troxerutin. The main questions it aims to answer are: - Does troxerutin lower the number of thrombotic events in participants? - What medical problems do participants have when taking troxerutin? Researchers will compare troxerutin to a placebo (a look-alike substance that contains no drug) to see if troxerutin works to prevent thrombotic events in COVID-19 patients. Participants will: - Take troxerutin or a placebo every day for 7 days. - Visit the clinic at the first, fourth, seventh and 28th days after enrollment for checkups and tests - Keep a diary of their symptoms and the number of times of thrombotic events, bleeding events and type II HIT-related thrombocytopenia

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• COVID 19 Associated Coagulopathy
• COVID-19

• NCT number: NCT06355258
• Study type: Interventional
• Source: Westlake University
• Contact: Xu Li, PhD
• Phone: 13811635032
• Email: lixu@westlake.edu.cn
• Status: Recruiting
• Phase: Phase 1
• Start date: September 15, 2023
• Completion date: March 2025